We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00083434
Recruitment Status : Terminated (This study was stopped because of an inadequate rate of enrollment.)
First Posted : May 26, 2004
Last Update Posted : April 27, 2011
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Brief Summary:
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Condition or disease Intervention/treatment Phase
Anemia Cancer Drug: Epoetin alfa Phase 3

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Study Start Date : February 2004
Study Completion Date : October 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Body weight >/= 99lbs
  • ECOG 0-2
  • Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
  • Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

Exclusion Criteria:

  • History of or concurrent second malignancy
  • Evidence of primary or metastatic malignancy involving the Central Nervous System

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00083434

United States, California
Advanced Urology Medical Center
Anaheim, California, United States, 92801
Shapiro, Stafford & Yee
Arcadia, California, United States, 91007
California Cancer Center
Fresno, California, United States, 93720
United States, Florida
Tukoi Research
North Miami, Florida, United States, 33161
United States, North Carolina
Hanover Medical Specialists, PA
Wilmington, North Carolina, United States, 28401
United States, Washington
Madigan Army Medical Center Urology Services
Tacoma, Washington, United States, 98431-5000
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Additional Information:
ClinicalTrials.gov Identifier: NCT00083434     History of Changes
Other Study ID Numbers: CR010549
First Posted: May 26, 2004    Key Record Dates
Last Update Posted: April 27, 2011
Last Verified: April 2011

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Additional relevant MeSH terms:
Epoetin Alfa